Triple therapy superior to dual therapy in HCV
As reported in Mayo Clinic Proceedings, treatment of hepatitis C virus-infected patients with triple therapy (pegylated-interferon, ribavirin, and teleprevir) is more effective than dual therapy (pegylated-interferon and ribavirin). Specifically, a sustained virologic response was achieved in 51% of treatment-naïve patients, 67% of patients with a prior non-response and 56% of patients with a prior relapse of patients treated with triple therapy compared to 37%, 11%, and 27% of patients treated with dual therapy, respectively.
s-H-FABP levels predict outcome in ICU patients
As reported in Clinical Research in Cardiology, the level of serum heart-type fatty acid-binding protein (s-H-FABP) is higher in ER patients admitted to the ICU than ER patients admitted to other departments. The s-H-FABP level was also higher in ICU non-survivors than ICU survivors. A s-H-FABP level of 20.95 ng/ml had a 81.1% and 66.0% sensitivity and specificity, respectively, for in-hospital mortality.
Green tea reduces BP and improves lipid profile
As reported in Nutrition, Metabolism, and Cardiovascular Diseases, a meta-analysis involved 20 RCTs and 1536 participants showed that consumption of green tea (Camellia sinensis) is associated with a reduction in systolic blood pressure (-1.94 mmHg) and improved lipid profile (TC, -0.13 mmol/l; LDL-C, -0.19 mmol/l). Additional studies quantifying the association are needed.